Lung Abnormalities in Liver Cirrhosis

Yaman Muli, Mustika Syifa
{"title":"Lung Abnormalities in Liver Cirrhosis","authors":"Yaman Muli, Mustika Syifa","doi":"10.29328/journal.jprr.1001045","DOIUrl":null,"url":null,"abstract":"This article aims to provide what lung disorders can be caused by liver cirrhosis and also explain the pathophysiology of each etiologies. Regardless of preexisting lung illness, patients suffering from liver cirrhosis, especially decompensated liver cirrhosis can develop distinct pulmonary complications. Liver cirrhosis patients should be assessed for hepatopulmonary syndrome (HPS), portopulmonary hypertension (PoPH), hepatic hydrothorax (HH), and spontaneous bacterial empyema (SBEM) which are the most clinically significant pulmonary consequences, in particular when dyspnea develops in conjunction with hepatic cirrhosis. These entities differ in terms of pathophysiology, clinical characteristics, diagnosis, and suitable treatment options. This emphasizes the need for a specific diagnostic algorithm in liver cirrhosis patients presenting with dyspnea or other pulmonary symptoms. These pulmonary complications might be rare in patients with liver cirrhosis and portal hypertension but these complications might carry significant morbidity and mortality risks and, therefore, strong clinical suspicion is required to make an early accurate diagnosis. There are several medical therapies available for each condition in multiple studies but most of the treatments and procedures don’t have a significant benefit or have short-lived benefits. The only treatment that changes the clinical prognosis of decompensated cirrhosis effectively in the long term is liver transplantation. However, liver transplantation also needs careful consideration as in some cases it might increase the risk of morbidity and mortality.","PeriodicalId":398097,"journal":{"name":"Journal of Pulmonology and Respiratory Research","volume":"26 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pulmonology and Respiratory Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29328/journal.jprr.1001045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

This article aims to provide what lung disorders can be caused by liver cirrhosis and also explain the pathophysiology of each etiologies. Regardless of preexisting lung illness, patients suffering from liver cirrhosis, especially decompensated liver cirrhosis can develop distinct pulmonary complications. Liver cirrhosis patients should be assessed for hepatopulmonary syndrome (HPS), portopulmonary hypertension (PoPH), hepatic hydrothorax (HH), and spontaneous bacterial empyema (SBEM) which are the most clinically significant pulmonary consequences, in particular when dyspnea develops in conjunction with hepatic cirrhosis. These entities differ in terms of pathophysiology, clinical characteristics, diagnosis, and suitable treatment options. This emphasizes the need for a specific diagnostic algorithm in liver cirrhosis patients presenting with dyspnea or other pulmonary symptoms. These pulmonary complications might be rare in patients with liver cirrhosis and portal hypertension but these complications might carry significant morbidity and mortality risks and, therefore, strong clinical suspicion is required to make an early accurate diagnosis. There are several medical therapies available for each condition in multiple studies but most of the treatments and procedures don’t have a significant benefit or have short-lived benefits. The only treatment that changes the clinical prognosis of decompensated cirrhosis effectively in the long term is liver transplantation. However, liver transplantation also needs careful consideration as in some cases it might increase the risk of morbidity and mortality.
肝硬化的肺部异常
本文旨在提供肝硬化可能引起的肺部疾病,并解释每种病因的病理生理学。无论先前是否存在肺部疾病,肝硬化患者,尤其是失代偿期肝硬化患者可出现明显的肺部并发症。肝硬化患者应评估肝肺综合征(HPS)、门脉性肺动脉高压(PoPH)、肝性胸水(HH)和自发性细菌性脓胸(SBEM),这些是最具临床意义的肺部后果,特别是当呼吸困难并发肝硬化时。这些实体在病理生理、临床特征、诊断和合适的治疗选择方面有所不同。这强调了在出现呼吸困难或其他肺部症状的肝硬化患者中需要一个特定的诊断算法。这些肺部并发症在肝硬化和门脉高压患者中可能很少见,但这些并发症可能具有显著的发病率和死亡率风险,因此需要强烈的临床怀疑才能早期准确诊断。在多项研究中,每种情况都有几种可用的医学治疗方法,但大多数治疗和程序都没有显著的益处或只有短暂的益处。长期有效改变失代偿期肝硬化临床预后的唯一治疗方法是肝移植。然而,肝移植也需要仔细考虑,因为在某些情况下它可能会增加发病率和死亡率的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信